BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27837619)

  • 21. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
    Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
    Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
    Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Expression Status and Prognostic Value of Cancer Stem Cell Biomarker CD133 in Cutaneous Squamous Cell Carcinoma.
    Xu R; Cai MY; Luo RZ; Tian X; Han JD; Chen MK
    JAMA Dermatol; 2016 Mar; 152(3):305-11. PubMed ID: 26560495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy.
    García VM; Batlle JF; Casado E; Burgos E; de Castro J; Belda C; Barriuso J; Sánchez JJ; García-Cabezas MÁ; González-Barón M; Cejas P
    Colorectal Dis; 2011 Sep; 13(9):989-98. PubMed ID: 20718834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma.
    Jiang S; Pei L; Yang ZL; Liu G
    Hepatogastroenterology; 2014 May; 61(131):574-9. PubMed ID: 26176038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinicopathological parameters significance of CD133 and Nestin in epithelial ovarian cancer: a meta-analysis.
    Zhao L; Li J; Liu M; Zhou H; Zou H; Wei Y; Sun K; Li G; Li S; Pang L
    Future Oncol; 2017 Dec; 13(28):2555-2570. PubMed ID: 29168665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.
    Altman AD; Nelson GS; Ghatage P; McIntyre JB; Capper D; Chu P; Nation JG; Karnezis AN; Han G; Kalloger SE; Köbel M
    Mod Pathol; 2013 Sep; 26(9):1255-63. PubMed ID: 23558569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma.
    Davidson B; Valborg Reinertsen K; Trinh D; Reed W; Bøhler PJ
    Hum Pathol; 2016 Aug; 54():64-73. PubMed ID: 27038683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.
    Xi HQ; Zhao P
    J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
    Kim WY; Shim SH; Jung HY; Dong M; Kim SN; Lee SJ
    Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas.
    Zambo I; Hermanova M; Zapletalova D; Skoda J; Mudry P; Kyr M; Zitterbart K; Sterba J; Veselska R
    Cancer Biomark; 2016 Jun; 17(1):107-16. PubMed ID: 27314299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
    Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
    J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of homeobox B-13 correlates with angiogenesis, aberrant expression of EMT markers, aggressive characteristics and poor prognosis in pancreatic carcinoma.
    Zhai LL; Wu Y; Cai CY; Tang ZG
    Int J Clin Exp Pathol; 2015; 8(6):6919-27. PubMed ID: 26261579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD133 expression is correlated with poor prognosis in colorectal cancer.
    Kashihara H; Shimada M; Kurita N; Iwata T; Sato H; Kozo Yoshikawa ; Higashijima J; Chikakiyo M; Nishi M; Matsumoto N
    Hepatogastroenterology; 2014 Sep; 61(134):1563-7. PubMed ID: 25436343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical value of CD133 and nestin in patients with glioma: a population-based study.
    Dahlrot RH; Hansen S; Jensen SS; Schrøder HD; Hjelmborg J; Kristensen BW
    Int J Clin Exp Pathol; 2014; 7(7):3739-51. PubMed ID: 25120750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors.
    Szubert S; Moszynski R; Michalak S; Nowicki M; Sajdak S; Szpurek D
    Microvasc Res; 2016 Sep; 107():91-6. PubMed ID: 27312585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas.
    Zheng W; Fadare O
    Int J Clin Exp Pathol; 2012; 5(3):182-6. PubMed ID: 22558471
    [No Abstract]   [Full Text] [Related]  

  • 40. Overexpression of PROM1 (CD133) confers poor prognosis in non-small cell lung cancer.
    Qiu ZX; Zhao S; Mo XM; Li WM
    Int J Clin Exp Pathol; 2015; 8(6):6589-95. PubMed ID: 26261540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.